JP2024521430A - 神経剤誘発性発作を治療する方法 - Google Patents
神経剤誘発性発作を治療する方法 Download PDFInfo
- Publication number
- JP2024521430A JP2024521430A JP2023575935A JP2023575935A JP2024521430A JP 2024521430 A JP2024521430 A JP 2024521430A JP 2023575935 A JP2023575935 A JP 2023575935A JP 2023575935 A JP2023575935 A JP 2023575935A JP 2024521430 A JP2024521430 A JP 2024521430A
- Authority
- JP
- Japan
- Prior art keywords
- benzodiazepine
- hours
- pharma
- prodrug
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D243/00—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms
- C07D243/06—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4
- C07D243/10—Heterocyclic compounds containing seven-membered rings having two nitrogen atoms as the only ring hetero atoms having the nitrogen atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D243/14—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines
- C07D243/16—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals
- C07D243/18—1,4-Benzodiazepines; Hydrogenated 1,4-benzodiazepines substituted in position 5 by aryl radicals substituted in position 2 by nitrogen, oxygen or sulfur atoms
- C07D243/24—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163208885P | 2021-06-09 | 2021-06-09 | |
| US63/208,885 | 2021-06-09 | ||
| PCT/US2022/032783 WO2022261287A1 (en) | 2021-06-09 | 2022-06-09 | Methods of treating nerve agent-induced seizures |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521430A true JP2024521430A (ja) | 2024-05-31 |
| JP2024521430A5 JP2024521430A5 (enExample) | 2025-06-13 |
Family
ID=84425551
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023575935A Pending JP2024521430A (ja) | 2021-06-09 | 2022-06-09 | 神経剤誘発性発作を治療する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240277696A1 (enExample) |
| EP (1) | EP4352047A4 (enExample) |
| JP (1) | JP2024521430A (enExample) |
| KR (1) | KR20240022544A (enExample) |
| CN (1) | CN117836284A (enExample) |
| AU (1) | AU2022291138A1 (enExample) |
| CA (1) | CA3222575A1 (enExample) |
| IL (1) | IL309097A (enExample) |
| MX (1) | MX2023014418A (enExample) |
| WO (1) | WO2022261287A1 (enExample) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1511741B1 (en) * | 2002-04-26 | 2012-12-26 | Eli Lilly And Company | Ester derivatives of a decahydroisoquinoline-3-carboxylic acid as analgestics |
| US11045462B2 (en) * | 2016-06-14 | 2021-06-29 | The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. | Methods for treating neurological conditions and exposure to nerve agents |
| WO2018169798A1 (en) * | 2017-03-11 | 2018-09-20 | The Regents Of The University Of California | Mitigation of cns disorders by combination therapy using neurosteroids, and ampa blockers |
-
2022
- 2022-06-09 KR KR1020247000572A patent/KR20240022544A/ko active Pending
- 2022-06-09 CN CN202280052288.XA patent/CN117836284A/zh active Pending
- 2022-06-09 US US18/566,735 patent/US20240277696A1/en active Pending
- 2022-06-09 MX MX2023014418A patent/MX2023014418A/es unknown
- 2022-06-09 IL IL309097A patent/IL309097A/en unknown
- 2022-06-09 JP JP2023575935A patent/JP2024521430A/ja active Pending
- 2022-06-09 EP EP22821009.2A patent/EP4352047A4/en active Pending
- 2022-06-09 AU AU2022291138A patent/AU2022291138A1/en active Pending
- 2022-06-09 CA CA3222575A patent/CA3222575A1/en active Pending
- 2022-06-09 WO PCT/US2022/032783 patent/WO2022261287A1/en not_active Ceased
Also Published As
| Publication number | Publication date |
|---|---|
| IL309097A (en) | 2024-02-01 |
| WO2022261287A1 (en) | 2022-12-15 |
| KR20240022544A (ko) | 2024-02-20 |
| MX2023014418A (es) | 2024-02-13 |
| CN117836284A (zh) | 2024-04-05 |
| EP4352047A4 (en) | 2025-04-16 |
| EP4352047A1 (en) | 2024-04-17 |
| US20240277696A1 (en) | 2024-08-22 |
| AU2022291138A1 (en) | 2023-12-07 |
| CA3222575A1 (en) | 2022-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA3087912A1 (en) | Prodrugs of ketamine, compositions and uses thereof | |
| JP7704680B2 (ja) | フェロトーシス誘導活性を有する化合物およびそれらの使用方法 | |
| KR20010014279A (ko) | 뮤 오피오이드 화합물의 호흡 저하 및 수반되는 부작용을감소시키기 위한 조성물 및 그 방법 | |
| JP2001509176A (ja) | インテグリンアンタゴニスト | |
| JP2001503060A (ja) | インテグリン拮抗薬 | |
| EP1428534B1 (en) | Benzofurazan derivatives for enhancing glutamatergic synaptic responses | |
| JP2008528602A (ja) | 鎮痛活性および／または免疫賦活活性を有する３−ヘテロ環−３−ヒドロキシ−２−アミノプロピオン酸アミドおよび関連化合物 | |
| US20100267728A1 (en) | 3-substituted-1,2,3-triazin-4-one's and 3 substituted 1,3-pyrimidinone's for enhancing glutamatergic synaptic responses | |
| AU2014231722B2 (en) | Salts, co-crystals, and polymorphs of an anxiolytic compound | |
| CA2996681A1 (en) | Inhibitors of tryptophan dioxygenases (ido1 and tdo) and their use in therapy | |
| EA012610B1 (ru) | Аналоги локсапина и фармацевтические композиции на их основе | |
| TW201022274A (en) | Dihydroetorphine | |
| CA3226724A1 (en) | Cyanopyridine and cyanopyrimidine bcl6 degraders | |
| JP2019504016A (ja) | アルキルジヒドロキノリンスルホンアミド化合物 | |
| CN111886010A (zh) | 用于治疗与etbr激活相关的癌症的氘化化合物、组合物和方法 | |
| WO2017106872A1 (en) | Alkynyl dihydroquinoline sulfonamide compounds | |
| TWI710559B (zh) | 新吡啶陽離子化合物、包含該化合物的藥學組成物、其用途及其製備方法 | |
| JP5466510B2 (ja) | シドノンイミン−特異的ドーパミン再摂取阻害剤およびそのドーパミン関連障害の治療における使用 | |
| JP2008543817A (ja) | 治療剤 | |
| KR20200081359A (ko) | 2-(5-(4-(2-모르폴리노에톡시)페닐)피리딘-2-일)-n-벤질아세트아미드의 고체 형태 | |
| JP2024521430A (ja) | 神経剤誘発性発作を治療する方法 | |
| EP3353163B1 (en) | 2,3,4,5-tetrahydropyridin-6-amine derivatives | |
| JP2014527962A (ja) | Ｔ型カルシウムチャネル遮断薬としてのテトラヒドロナフタレン誘導体 | |
| US8168632B2 (en) | Bicyclic amide derivatives for the treatment of respiratory disorders | |
| US20130109660A1 (en) | Novel pyrimidinecarboxamide derivatives |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20250605 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20250605 |